SPOTLIGHT -
Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis
Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.
Read More
Dr. Yacoub on Efficacy and Safety Results With Parsaclisib in Myelofibrosis
Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.
Dr. Yacoub on the Rationale For Parsaclisib After Suboptimal Response to Ruxolitinib in Myelofibrosis
Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.
Dr. Yacoub on Pegylated Interferon Treatment for PV
Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
